Metabolomics Diagnostics Announces Partnership with US company Renegade.bio
to Launch Preeclampsia Test in USA Market
Cork Ireland and San Francisco Ca. Feb. 15, 2022 – Irish diagnostics company Metabolomics Diagnostics announces today its partnership with Bay Area biotech firm renegade.bio. The partnership will deliver a novel preeclampsia risk screening test to the US market in late 2022.
Preeclampsia can cause premature birth, infant and maternal mortality, and can lead to lifelong health complications for mother and baby.
The test will be jointly developed specifically for the US population by the partnership, improving upon available assessments by creating a personalized risk profile for individuals. It measures a proprietary panel of biomarkers in pregnancy bloods that serve as early indicators of preeclampsia risk. This provides maternal health physicians with the insights to better identify those pregnant women at risk, and to improve their pregnancy outcomes.
“We have been in discussions with several potential partners in the USA market over the past number of months to bring our preeclampsia risk screening technology to the US market. We strategically selected renegade.bio for its clinical laboratory expertise in developing novel diagnostics and its mission to ensure equitable access to care within local communities,” said Robin Tuytten, CEO of Metabolomics Diagnostics. “This partnership is fully aligned with our mission to enable screening of every woman for risk. We see this as the beginning of a relationship which will see further innovative diagnostics with real impact reaching the wider populations. Together we aim to significantly improve population health.”
“Our partnership with Metabolomics Diagnostics demonstrates the mission of renegade.bio to expand community-based health solutions testing to include women’s reproductive and sexual health, particularly among traditionally underserved communities,” said Craig Rouskey, CEO and co-founder of renegade.bio. “The team at Metabolomics Diagnostics is world class, has deep clinical and diagnostic expertise and the benefit of access to significant sample biobanks and patient data to support their research to date.”
About Metabolomics Diagnostics
Based in Ireland, Metabolomic Diagnostic’s high-performance R&D team has developed an effective pipeline to firstly identify diagnostic biomarker panels and then translate these panels into clinical assays ready for application in the clinical laboratory. This pipeline combines the biomarker multiplexing capabilities of Mass Spectrometry, a powerful analytical technology, with the company’s own informatics and statistics solutions to deliver diagnostic innovation. This is reflected in Metabolomic Diagnostics’ strong and versatile IP portfolio of technical innovations and biomarkers. www.metabolomicdiagnostics.com
About renegade.bio
Renegade.bio is a purpose-driven, LGBTQ-led public benefit corporation demanding better health and healthcare for all people. With roots in activism, renegade.bio’s team focuses on improving access to diagnostics. It develops health solutions for everyone — especially historically underserved populations, such as women, LBGTQ and BIPOC communities.
For information about the company, products and services, visit www.renegade.bio.
Media Contact: Hillary Cronin Hillary.cronin@metabolomicdiagnostics.com +353 21 4510263